WHAT IS CLAIMED IS;

1. Use of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for reducing serum uric levels in a human, wherein the medicament is adapted for administration of less than 40 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid.

2. The use of claim 1 for the manufacture of a medicament, wherein the medicament is adapted for administration of about 10 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof~~, is administered to the human~~.

3. The use of claim 1 for the manufacture of a medicament, wherein the medicament is adapted for administration of about 20 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

4. The use of claim 1 for the manufacture of a medicament, wherein the medicament is adapted for administration of less than 20 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

5. The use of claim 1 for the manufacture of a medicament, wherein the medicament is adapted for administration of about 5 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

6. The use of claim 1 for the manufacture of a medicament, wherein the medicament is adapted for administration of less than 5 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

7. The use of claim 1 for the manufacture of a medicament, wherein the medicament is adapted for administration of about 2 mg per day of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

8. The use of claim 1 for the manufacture of a medicament , wherein 24 hours after administration of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof, the serum uric acid levels are reduced by at least 1 mg/dL.

9. The use according to any one of claims 1-7, wherein 24 hours after administration of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, serum uric acid levels are reduced by at least 15% from baseline.

10. The use according to any one of claims 1-7, wherein 24 hours after administration of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof, serum uric acid levels are reduced by at least 20% from baseline.

11. The use according to any one of the preceding claims, for treating or preventing a condition characterized by abnormal tissue or organ levels of uric acid.

12. The use of claim 11, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, ~~a cardiovascular disease,~~ coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, ~~hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency~~ or a combination thereof.

13. The use of claim 12, wherein the condition is gout.

14. The use of claim 1, wherein the medicament is adapted for administration with a second agent effective for the treatment of the gout ~~is administered to the human~~.

15. The use of claim 14, wherein the second agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, a xanthine oxidoreductase inhibitor, or combinations thereof.

~~16. The use of claim 15, wherein the URAT 1 inhibitor is 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)acetic acid, or a pharmaceutically acceptable salt thereof.~~

~~17.~~16. The use of claim 15, wherein the xanthine oxidase inhibitor is allopurinol or febuxostat.

~~18.~~17. A pharmaceutical composition comprising less than 40mg of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

~~19.~~18. The pharmaceutical composition of claim ~~18~~17, comprising less than 20mg of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

~~20.~~19. The pharmaceutical composition of claim ~~18~~17, comprising about 20mg of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

~~21.~~20. The pharmaceutical composition of claim ~~18~~17, comprising about 10mg of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

~~22.~~21. The pharmaceutical composition of claim ~~18~~17, comprising less than 5mg of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.

~~23.~~22. The pharmaceutical composition of claim ~~18~~17, comprising about 5mg of 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.